ReviewCurrent psychiatry reports2025
Clonidine for Management of Agitation in Delirious Patients.
Review in Current psychiatry reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review explores clonidine as a potential treatment for agitation across various clinical contexts, focusing on its application in patients with limited cognitive reserve, hyperactive delirium, or conditions where standard treatments may exacerbate underlying symptoms, such as Parkinsonism. The review evaluates the pharmacological properties, efficacy, and practical considerations for using clonidine in managing agitation, including its role in other psychiatric and medical conditions. RECENT
findingsClonidine, a centrally acting alpha-2 adrenergic agonist, reduces norepinephrine release, leading to sedation, anxiolysis, and analgesia without significant respiratory depression. Recent studies and case reports highlight its utility in managing agitation, ADHD, autism spectrum disorders, dementia, and hyperactive delirium. Clonidine has demonstrated advantages over antipsychotics in preserving cognitive function and minimizing delirium duration. Additionally, it shows promise in treating PTSD-related nightmares and as an adjunct in anesthesia and analgesia. Clonidine offers a well-tolerated, cost-effective alternative to antipsychotics for managing agitation, particularly in vulnerable populations. Its diverse applications, favorable safety profile, and minimal impact on Parkinsonism make it a valuable tool in psychiatry and medicine. Further research is needed to refine dosing protocols and expand its indications in managing agitation and related symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.